{"id":"NCT03780959","sponsor":"Amgen","briefTitle":"Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)","officialTitle":"Safety, Population Pharmacokinetics, and Efficacy of Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) in Children With Juvenile Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"1997-05-01","primaryCompletion":"1998-07-08","completion":"1998-07-08","firstPosted":"2018-12-19","resultsPosted":"2019-08-02","lastUpdate":"2019-08-02"},"enrollment":69,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Etanercept","otherNames":["Enbrel","TNFR:Fc"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Etanercept/Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Etanercept/Etanercept","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to determine the efficacy of etanercept in children with polyarticular course JRA.","primaryOutcome":{"measure":"Percentage of Participants With Disease Flare in Part 2","timeFrame":"End of part 1 (day 90) and months 4 to 7","effectByArm":[{"arm":"Part 2: Placebo","deltaMin":81,"sd":null},{"arm":"Part 2: Etanercept 0.4 mg/kg","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0030"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":69},"commonTop":["Upper respiratory tract infection","Injection site erythema","Headache","Injection site swelling","Injection site pruritus"]}}